The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%,

Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

Key Market Insights

§  Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems

§  Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors

§  The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains

§  Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry

§  The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics

§  Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments

§  Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%

§  In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

Table of Contents

1.         PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines                     

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1        Chapter Overview

3.2.       Overview of Biopharmaceuticals

3.3.       Expression Systems Used for Biopharmaceutical Production

3.3.1.    Microbial Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Fungal Expression Systems

3.3.1.3. Yeast Expression Systems                   

3.3.2.    Mammalian versus Microbial Expression Systems

3.4.       Microbial Manufacturing Process

3.4.1.    Cell Banking

3.4.2.    Upstream Processing

3.4.3.    Fermentation

3.4.4.    Downstream Processing

3.5.       Overview of Contract Manufacturing

3.6.       Need for Outsourcing Microbial Biomanufacturing Operations

3.7.       Commonly Outsourced Microbial Biomanufacturing Operations

3.8.       Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations

3.9.       Key Considerations while Selecting a CMO Partner

3.10.     Concluding Remarks     

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Microbial Contract Biomanufacturing Market: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Location of Manufacturing Facility

4.2.5.    Analysis by Scale of Operation

4.2.6.    Analysis by Type of Biologic

4.2.7.    Analysis by Type of Expression System Used

4.2.8.    Analysis by Type of Fermenter

4.2.9.    Analysis by Type of Service(s) Offered

4.2.10.  Analysis by Regulatory Accreditations / Certifications

4.3.       Regional Analysis

4.3.1.    Analysis by North America

4.3.2.    Analysis by Europe

4.3.3.    Analysis by Asia Pacific

4.3.4.    Analysis by Middle East and North Africa

5.         COMPANY COMPETITIVENESS ANALYSIS

5.1.       Chapter Overview

5.2.       Assumptions and Key Parameters

5.3.       Methodology

5.4.       Competitiveness Analysis

5.4.1.    Competitiveness Analysis: Companies in North America

5.4.2.    Competitiveness Analysis: Companies in Europe

5.4.3.    Competitiveness Analysis: Companies in Asia Pacific    

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Microbial Contract Biomanufacturers based in North America

6.2.1.    AGC Biologics

6.2.1.1. Company Overview

6.2.1.2. Service Portfolio

6.2.1.3. Manufacturing Capabilities and Facilities

6.2.1.4. Recent Developments and Future Outlook

6.2.2.    Aldevron

6.2.2.1. Company Overview

6.2.2.2. Service Portfolio

6.2.2.3. Manufacturing Capabilities and Facilities

6.2.2.4. Recent Developments and Future Outlook

6.2.3.    BioVectra

6.2.3.1. Company Overview

6.2.3.2. Service Portfolio

6.2.3.3. Manufacturing Capabilities and Facilities

6.2.3.4. Recent Developments and Future Outlook

6.2.4.    Ology Bioservices

6.2.4.1. Company Overview

6.2.4.2. Service Portfolio

6.2.4.3. Manufacturing Capabilities and Facilities

6.2.4.4. Recent Developments and Future Outlook

6.3.       Microbial Contract Biomanufacturers Based in Europe

6.3.1.    Eurogentec

6.3.1.1. Company Overview

6.3.1.2. Service Portfolio

6.3.1.3. Manufacturing Capabilities and Facilities

6.3.1.4. Recent Developments and Future Outlook

6.3.2.    Northway Biotechpharma

6.3.2.1. Company Overview

6.3.2.2. Service Portfolio

6.3.2.3. Manufacturing Capabilities and Facilities

6.3.2.4. Recent Developments and Future Outlook

6.3.3.    Porton Biopharma

6.3.3.1. Company Overview

6.3.3.2. Service Portfolio

6.3.3.3. Manufacturing Capabilities and Facilities

6.3.3.4. Recent Developments and Future Outlook

6.4.       Microbial Contract Biomanufacturers Based in Asia Pacific

6.4.1.    EirGenix

6.4.1.1. Company Overview

6.4.1.2. Service Portfolio

6.4.1.3. Manufacturing Capabilities and Facilities

6.4.1.4. Recent Developments and Future Outlook

6.4.2.    Etinpro

6.4.2.1. Company Overview

6.4.2.2. Service Portfolio

6.4.2.3. Manufacturing Capabilities and Facilities

6.4.2.4. Recent Developments and Future Outlook

6.4.3.    Stelis Biopharma

6.4.3.1. Company Overview

6.4.3.2. Service Portfolio

6.4.3.3. Manufacturing Capabilities and Facilities

6.4.3.4. Recent Developments and Future Outlook

7.         RECENT PARTNERSHIPS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Microbial Contract Biomanufacturers: Recent Partnerships

7.3.1.    Analysis by Year of Partnerships

7.3.2.    Analysis by Type of Partnership Model

7.3.3.    Analysis by Scale of Operation

7.3.4.    Analysis by Type of Biologic

7.3.5.    Analysis by Focus Area

7.3.6.    Analysis by Target Therapeutic Area

7.3.7.    Analysis by Region

7.3.7.1. Country-Wise Distribution

7.3.7.2. Intercontinental and Intracontinental Agreements

7.3.8.    Most Active Players: Analysis by Number of Partnerships

7.4.       Microbial Contract Biomanufacturers: Mergers and Acquisitions

7.4.1.    Analysis by Year of Merger / Acquisition

7.4.2.    Analysis by Type of Acquisition 

7.4.3.    Regional Analysis 

7.4.3.1. Continent-wise Distribution 

7.4.3.2. Country-wise Distribution 

7.4.3.3. Intercontinental and Intracontinental Deals 

7.4.4.    Most Active Players: Analysis by Number of Acquisitions

7.4.5.    Analysis by Key Value Drivers  

7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers

8.         RECENT EXPANSIONS

8.1.       Chapter Overview

8.2.       Microbial Contract Biomanufacturers: Recent Expansions

8.2.1.    Analysis by Year of Expansion

8.2.2.    Analysis by Type of Expansion

8.2.3.    Analysis by Scale of Operation

8.2.4.    Analysis by Type of Biologic

8.3.       Geographical Analysis

8.3.1.    Continent-wise Distribution                   

9.         MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS

9.1.       Chapter Overview

9.2.       Technology Platforms Commonly Used for Microbial Fermentation

9.3.       Upcoming Platforms-General Technologies

10.        ATTRACTIVENESS COMPETITION MATRIX

10.1.     Chapter Overview

10.2.     AC Matrix: An Overview

10.2.1.  Strong Business Segment

10.2.2.  Average Business Segment

10.2.3.  Weak Business Segment

10.3.     AC Matrix: Analytical Methodology

10.4.     AC Matrix: Analyzing the Data for North America

10.5.     AC Matrix: Analyzing the Data for Europe

10.6.     AC Matrix: Analyzing the Data for Asia Pacific and Middle East

11.        MAKE VERSUS BUY DECISION MAKING FRAMEWORK

11.1.     Chapter Overview

11.2.     Assumptions and Parameter Definitions

11.2.1.  Scenario 1

11.2.2.  Scenario 2

11.2.3.  Scenario 3

11.2.4.  Scenario 4

11.3.     Concluding Remarks

12.        BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING

12.1.     Chapter Overview

12.2.     List of Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players

12.2.1.  Analysis by Number of Initiatives

12.2.2.  Analysis by Year of Initiative

12.2.3.  Analysis by Company and Year of Initiative

12.2.4.  Analysis by Purpose of Initiative

12.2.5.  Analysis by Company and Purpose of Initiative

12.2.6.  Analysis by Type of Initiative

12.2.7.  Analysis by Scale of Operation

12.2.8.  Analysis by Type of Drug Molecule

12.2.9.  Analysis by Type of Microbial Expression System Used              

12.2.10. Geographical Analysis by Investment Made

12.3.     Competitive Benchmarking of Big Pharmaceutical Players

12.3.1. Big Pharma Summary

13.        CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE                           MOLECULE DRUGS / THERAPIES

13.1.     Chapter Overview

13.2.     Small Molecule and Large Molecule Drugs / Therapies    

13.2.1. Comparison of Key Characteristics

13.2.2. Comparison of Microbial Manufacturing Process

13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules

13.2.3. Comparison of Key Manufacturing-related Challenges

14.        MARKET SIZING AND OPPORTUNITY ANALYSIS

14.1.     Chapter Overview

14.2.     Key Assumptions and Forecast Methodology

14.3.     Overall Microbial Contract Biomanufacturing Market, 2020-2030

14.3.1.  Microbial Contract Biomanufacturing Market for APIs, 2020-2030

14.3.2.  Microbial Contract Biomanufacturing Market for FDFs, 2020-2030           

14.4.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic

14.5.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used

14.6.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation

14.7.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of           End User

14.8.      Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions          

14.8.1.   Microbial Contract Biomanufacturing Market in North America, 2020-2030

14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins

14.8.1.2. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes

14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth   Hormones

14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody-based Drugs

14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics

14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems

14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations

14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations

14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies

14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies

14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies

14.8.2.    Microbial Contract Biomanufacturing Market in Europe, 2020-2030

14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins

14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes

14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones

14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody-based Drugs

14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics

14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems

14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations

14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations

14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies

14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized    Companies

14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies

14.8.3.  Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030

14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins

14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes

14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones

14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody- based Drugs

14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics

14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems

14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations

14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations

14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies

14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies

14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies

14.8.4.  Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030

14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins

14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Enzymes

14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Growth Hormones

14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Antibody-based Drugs

14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Other Biologics

14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Bacterial Cell-based Expression Systems

14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems

14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations

14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations

14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Small Companies

14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Mid-sized Companies

14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Large / Very Large Companies

14.8.5.  Microbial Contract Biomanufacturing Market in Latin America, 2020-2030

15.        IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET

15.1.     Chapter Overview

15.2.     Current Options and Recuperative Initiatives of Key Players

15.2.1.  KBI Biopharma

15.2.2.  Lonza

15.2.3.  Porton Pharma Solutions

15.2.4.  Wacker Biotech

15.2.5.  Wuxi AppTec

15.3.     Impact on Microbial Contract Biomanufacturing Market Opportunity

15.4.     Recuperative Strategies for CMO Businesses

15.4.1.  Strategies for Implementation in the Short / Mid Term

15.4.2.  Strategies for Implementation in the Long Term

16.        SWOT ANALYSIS

16.1.     Chapter Overview

16.2.     Strengths

16.3.     Weaknesses

16.4.     Opportunities

16.5.     Threats

16.6.     Comparison of SWOT Factors

17.        CONCLUDING REMARKS

17.1.     Chapter Overview

18.        INTERVIEW TRANSCRIPTS

18.1.     Chapter Overview

18.2.     Meteoric Biopharmaceuticals

18.2.1.  Company Snapshot

18.2.2.  Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)

18.3.     List Biological Laboratories

18.3.1.  Company Snapshot

18.3.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)

18.4.     OLON

18.4.1.  Company Snapshot

18.4.2.  Interview Transcript: Andrea Conforto, Sales and Marketing-Bioservices Director)

18.5.     Luina Bio

18.5.1.  Company Snapshot

18.5.2.  Interview Transcript: Max Rossetto, General Manager-Business Development

18.6.     WACKER Biotech

18.6.1.  Company Snapshot

18.6.2.  Interview Transcript: Rob van Dijk, Business Development Manager (Q4 2019)

19.        APPENDIX 1: TABULATED DATA

20.        APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com